Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. / Riesgo de infección asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biológicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevención.
Gastroenterol Hepatol
; 44(8): 587-598, 2021 Oct.
Article
in English, Spanish
| MEDLINE | ID: covidwho-1626213
ABSTRACT
Patients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Bacterial Infections
/
Biological Therapy
/
Virus Diseases
/
Inflammatory Bowel Diseases
/
Janus Kinase Inhibitors
/
Immunosuppressive Agents
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
/
Spanish
Journal:
Gastroenterol Hepatol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS